These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25911022)

  • 1. Gastrointestinal symptoms in late-onset Pompe disease: Early response to enzyme replacement therapy.
    Pardo J; García-Sobrino T; López-Ferreiro A
    J Neurol Sci; 2015; 353(1-2):181-2. PubMed ID: 25911022
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and histologic ocular findings in pompe disease.
    Yanovitch TL; Banugaria SG; Proia AD; Kishnani PS
    J Pediatr Ophthalmol Strabismus; 2010; 47(1):34-40. PubMed ID: 20128552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical guidelines for late-onset Pompe disease.
    Barba-Romero MA; Barrot E; Bautista-Lorite J; Gutierrez-Rivas E; Illa I; Jimenez LM; Ley-Martos M; Lopez de Munain A; Pardo J; Pascual-Pascual SI; Perez-Lopez J; Solera J; Vilchez-Padilla JJ
    Rev Neurol; 2012 Apr; 54(8):497-507. PubMed ID: 22492103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low anal sphincter tone in infantile-onset Pompe Disease: an emerging clinical issue in enzyme replacement therapy patients requiring special attention.
    Tan QK; Cheah SM; Dearmey SM; Kishnani PS
    Mol Genet Metab; 2013 Feb; 108(2):142-4. PubMed ID: 23266370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
    Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition.
    Remiche G; Herbaut AG; Ronchi D; Lamperti C; Magri F; Moggio M; Bresolin N; Comi GP
    Eur Neurol; 2012; 68(2):75-8. PubMed ID: 22760201
    [No Abstract]   [Full Text] [Related]  

  • 9. Obstructive sleep apnea in late-onset Pompe disease treated by enzyme replacement therapy.
    Bhui R; Spector AR
    Neuromuscul Disord; 2020 Apr; 30(4):329-330. PubMed ID: 32173248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus treatment recommendations for late-onset Pompe disease.
    Cupler EJ; Berger KI; Leshner RT; Wolfe GI; Han JJ; Barohn RJ; Kissel JT;
    Muscle Nerve; 2012 Mar; 45(3):319-33. PubMed ID: 22173792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Dimopoulos F; Papadimas GK; Papadopoulos C; Spengos K; Fatouros I; Kavouras SA; Manta P
    Mol Genet Metab; 2011 Nov; 104(3):279-83. PubMed ID: 21640624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of severe cardiomyopathy in infantile Pompe disease.
    Parent JJ; Schamberger M
    Cardiol Young; 2015 Jan; 25(1):146-8. PubMed ID: 25544546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening.
    Chien YH; Lee NC; Huang HJ; Thurberg BL; Tsai FJ; Hwu WL
    J Pediatr; 2011 Jun; 158(6):1023-1027.e1. PubMed ID: 21232767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Enzyme Replacement Therapy for Pompe Disease: The Long-Term Efficacy and Limitation].
    Fukuda T; Sugie H
    Brain Nerve; 2015 Sep; 67(9):1091-8. PubMed ID: 26329149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dilated Cerebral Arteriopathy in Classical Pompe Disease: A Novel Finding.
    Viamonte M; Tuna I; Rees J
    Pediatr Neurol; 2020 Jul; 108():117-120. PubMed ID: 32248988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into therapeutic options for Pompe disease.
    Richard E; Douillard-Guilloux G; Caillaud C
    IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease.
    Sacconi S; Wahbi K; Theodore G; Garcia J; Salviati L; Bouhour F; Vial C; Duboc D; Laforêt P; Desnuelle C
    Neuromuscul Disord; 2014 Jul; 24(7):648-50. PubMed ID: 24844452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.